Craig Wilson

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

William B. White, Christopher P. Cannon, Simon Heller et al. · New England Journal of Medicine · 2013 · 2.5K citations · Full text

Medicine, Cardiology, Internal Medicine +14

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial

Faı̈ez Zannad, Christopher P. Cannon, William C. Cushman et al. · The Lancet · 2015 · 754 citations · Full text

Medicine, Cardiology, Internal Medicine +17

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control

Ralph A. DeFronzo, P. Fleck, Craig Wilson et al. · Diabetes Care · 2008 · 224 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE)

William B. White, George L. Bakris, Richard M. Bergenstal et al. · American Heart Journal · 2011 · 152 citations

Medicine, Cardiology, Internal Medicine +17

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

Richard E. Pratley, Jane E.B. Reusch, P. Fleck et al. · Current Medical Research and Opinion · 2009 · 132 citations

Medicine, Pharmacology, Pharmacotherapy +17